A U.S. Food and Drug Administration (FDA) advisory committee has unanimously recommended the approval of Moderna’s mRNA-based seasonal influenza vaccine for adults aged 50 and older. The Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 9-0 on June 25, 2024, concluding that the data provided by the manufacturer supports the safety and efficacy of the vaccine, known as mRNA-1010, for the specified age group. This decision marks a significant regulatory milestone as the agency evaluates the potential for messenger RNA technology to expand beyond COVID-19 prevention into the broader respiratory virus market.
The committee’s recommendation serves as a critical step in the FDA’s formal approval process. While the agency is not legally bound to follow the advice of its advisory panels, it typically aligns with their consensus. The unanimous vote suggests a high level of confidence among the independent experts regarding the clinical trial data presented during the June meeting. According to the official FDA meeting record, the committee reviewed evidence from phase 3 clinical trials, which assessed the vaccine’s ability to elicit an immune response against various influenza strains compared to currently available, licensed flu shots.
The Evolving Landscape of mRNA Technology
The recommendation for an mRNA influenza vaccine represents the first time the FDA has moved toward authorizing this specific platform for seasonal flu. Traditional flu vaccines typically rely on egg-based or cell-based manufacturing processes, which can take months to produce and may lead to reduced efficacy if the circulating flu strains mutate significantly during the production window. mRNA technology, which gained widespread public recognition through its role in COVID-19 vaccines, allows for a more rapid design and manufacturing cycle.
Moderna’s mRNA-1010 is designed to encode for hemagglutinin proteins from four different influenza strains. During the proceedings reported by Reuters, company representatives emphasized that the mRNA platform could potentially offer better protection for older adults, who often experience weaker immune responses to standard-dose influenza vaccines. By prompting the body’s own cells to produce the viral proteins, the vaccine aims to trigger a robust immune system response that mirrors natural infection without the risk of illness.
Clinical Efficacy and Safety Data
The safety profile of mRNA-1010 was a primary focus of the committee’s deliberations. Clinical trials for the vaccine involved thousands of participants, and the data provided to the FDA indicated that the most common side effects included injection site pain, fatigue, and muscle aches—symptoms consistent with other mRNA vaccines currently on the market. The committee members reviewed whether these side effects would be acceptable for a seasonal vaccine that requires annual administration.
According to the analysis published by STAT News, the efficacy data showed that the vaccine met the non-inferiority criteria against current standard-of-care shots for influenza A strains. However, the performance against influenza B strains remained a point of technical discussion during the hearing. The committee ultimately concluded that the potential public health benefits, particularly for the 50-plus demographic which faces higher risks of hospitalization from flu complications, outweighed the identified risks.
What Happens Next for Regulatory Approval
Following the unanimous recommendation, the FDA will continue its internal review of the application submitted by Moderna. The agency is expected to finalize its decision on whether to grant formal approval for the vaccine’s commercial distribution. If approved, the product would join an increasingly competitive market of high-dose and adjuvanted flu vaccines specifically tailored for older adults.
The next major checkpoint involves the FDA’s final regulatory determination, which will confirm the product’s labeling and authorized indications. While the agency has not provided a specific date for a final decision, the regulatory cycle for such applications typically spans several months following an advisory committee recommendation. The public can monitor the official FDA portal for vaccines for updates regarding future authorizations and the inclusion of new products in the annual influenza immunization strategy. We encourage readers to share their thoughts or questions in the comments section below as this story develops.
Related reading